Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: against (297), hostile (2), resistant (74)

MyelomaPAD-Bortezomib(SC)DexamethasoneDoxorubicinVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA PAD (SC)-BORTEZOMIB (SC)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (SC)-Bortezom
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibSCDexamethasoneDoxorubicinVer1.pdf

MyelomaPAD-Bortezomib(IV)DexamethasoneDoxorubicinVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA PAD (IV)-BORTEZOMIB (IV)-DEXAMETHASONE-DOXORUBICIN Regimen Multiple Myeloma – PAD (IV)-Bortezom
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibIVDexamethasoneDoxorubicinVer1.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day) Regimen Multiple Myeloma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Peptide receptor radionuclide therapy (PRRT) - patient information

Description: This factsheet explains what peptide receptor radionuclide therapy (PRRT) is, what the therapy involves, and what the possible benefits and risks
Url: /Media/UHS-website-2019/Patientinformation/Scansandx-rays/Peptide-receptor-radionuclide-therapy-PRRT-3016-PIL.pdf

Azacitidine5

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5 days) This is an unlicens
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5.pdf

Azacitidine5+2Ver1

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5+2 days) This is not a lic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5-2Ver1.pdf

Bevacizumab-Irinotecan Ver 1.1

Description: Chemotherapy Protocol COLORECTAL CANCER BEVACIZUMAB-IRINOTECAN This protocol may require funding Regimen Colorectal Cancer –
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Bevacizumab-IrinotecanVer11.pdf

Bevacizumab-Fluorouracil-Folinic Acid-Oxaliplatin

Description: Chemotherapy Protocol COLORECTAL CANCER BEVACIZUMAB-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)OXALIPLATIN This regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Bevacizumab-Fluorouracil-FolinicAcid-Oxaliplatin.pdf

Bevacizumab-Fluorouracil-Folinic Acid-Irinotecan

Description: Chemotherapy Protocol COLORECTAL CANCER BEVACIZUMAB-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)IRINOTECAN This regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Bevacizumab-Fluorouracil-FolinicAcid-Irinotecan.pdf

121 to 130 of 417

Previous … 11 12 13 14 15 … Next